Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulsatile versus continuous oxytocin with restricted versus liberal IV fluids for induction of labour
ACTRN12624001282572Phase 4Not yet recruiting
- Sponsor
- Northern Health
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of oxytocin, sponsored by Northern Health. Primary endpoint: Duration of labour. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
oxytocin
Beyond the preview
Go deeper on ACTRN12624001282572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001282572.